Cassava Sciences Reports Full-year 2023 Financial Results

$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over...

Related Keywords

Canada ,Texas ,United States ,Puerto Rico ,France ,Australia ,South Korea ,New York ,Pierre Gravier ,Remi Barbier ,Eric Schoen ,Robert Anderson Jr ,Cassava Sciences Inc ,Cochin Institute Paris ,City University Of New York ,Drug Administration ,Nasdaq ,Orrick Herrington Sutcliffe ,Cassava Sciences ,Company Board Of Directors ,Research International ,Clinical Program ,Cash Equivalents ,Participants Have Completed Our Phase ,Data Readout ,Week Phase ,Expected Year End ,Outside Counsel Has Found No Evidence ,Substantiate Allegations ,Research Misconduct ,Cassava Science ,Chief Financial ,Clause Nicaise ,Robert Anderson ,Safety Monitoring Board ,Cassava Science Phase ,Cochin Institute ,Premier Research International ,Clinical Dementia Rating ,Global Scale ,Baseline Characteristics ,Analysis Plan ,Extension Study ,City University ,Orrick Herrington ,More Information Contact ,Note Regarding Forward Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Financial Tables Follow ,Ended December ,